Literature DB >> 18273557

Docking and multivariate methods to explore HIV-1 drug-resistance: a comparative analysis.

Anna Maria Almerico1, Marco Tutone, Antonino Lauria.   

Abstract

In this paper we describe a comparative analysis between multivariate and docking methods in the study of the drug resistance to the reverse transcriptase and the protease inhibitors. In our early papers we developed a simple but efficient method to evaluate the features of compounds that are less likely to trigger resistance or are effective against mutant HIV strains, using the multivariate statistical procedures PCA and DA. In the attempt to create a more solid background for the prediction of susceptibility or resistance, we carried out a comparative analysis between our previous multivariate approach and molecular docking study. The intent of this paper is not only to find further support to the results obtained by the combined use of PCA and DA, but also to evidence the structural features, in terms of molecular descriptors, similarity, and energetic contributions, derived from docking, which can account for the arising of drug-resistance against mutant strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18273557     DOI: 10.1007/s10822-008-9186-7

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  21 in total

1.  A general and fast scoring function for protein-ligand interactions: a simplified potential approach.

Authors:  I Muegge; Y C Martin
Journal:  J Med Chem       Date:  1999-03-11       Impact factor: 7.446

2.  Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.

Authors:  Mark D Shenderovich; Ron M Kagan; Peter N R Heseltine; Kal Ramnarayan
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

3.  A multivariate analysis of HIV-1 protease inhibitors and resistance induced by mutation.

Authors:  Anna Maria Almerico; Marco Tutone; Antonino Lauria; Patrizia Diana; Paola Barraja; Alessandra Montalbano; Girolamo Cirrincione; Gaetano Dattolo
Journal:  J Chem Inf Model       Date:  2006 Jan-Feb       Impact factor: 4.956

4.  Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.

Authors:  C Pérez; M Pastor; A R Ortiz; F Gago
Journal:  J Med Chem       Date:  1998-03-12       Impact factor: 7.446

5.  Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  R Schuurman; L Demeter; P Reichelderfer; J Tijnagel; T de Groot; C Boucher
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

6.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  J D Baxter; D L Mayers; D N Wentworth; J D Neaton; M L Hoover; M A Winters; S B Mannheimer; M A Thompson; D I Abrams; B J Brizz; J P Ioannidis; T C Merigan
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

Review 7.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

8.  Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties.

Authors:  Anil C Nair; Philippa Jayatilleke; Xia Wang; Stanislav Miertus; William J Welsh
Journal:  J Med Chem       Date:  2002-02-14       Impact factor: 7.446

9.  Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.

Authors:  M Holodniy; D Katzenstein; M Winters; J Montoya; R Shafer; M Kozal; M Ragni; T C Merigan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-04

10.  Strategies for long-term success in the treatment of HIV infection.

Authors:  J E Gallant
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

View more
  6 in total

1.  Molecular dynamics, dynamic site mapping, and highthroughput virtual screening on leptin and the Ob receptor as anti-obesity target.

Authors:  Marco Tutone; Licia Pantano; Antonino Lauria; Anna Maria Almerico
Journal:  J Mol Model       Date:  2014-05-06       Impact factor: 1.810

Review 2.  Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem.

Authors:  Ge-Fei Hao; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Drug Discov Today       Date:  2012-07-10       Impact factor: 7.851

3.  Molecular docking studies of marine diterpenes as inhibitors of wild-type and mutants HIV-1 reverse transcriptase.

Authors:  Leonardo A Miceli; Valéria L Teixeira; Helena C Castro; Carlos R Rodrigues; Juliana F R Mello; Magaly G Albuquerque; Lucio M Cabral; Monique A de Brito; Alessandra M T de Souza
Journal:  Mar Drugs       Date:  2013-10-29       Impact factor: 5.118

4.  Deciphering the Potential of Pre and Pro-Vitamin D of Mushrooms against Mpro and PLpro Proteases of COVID-19: An In Silico Approach.

Authors:  Abhay Tiwari; Garima Singh; Gourav Choudhir; Mohit Motiwale; Nidhi Joshi; Vasudha Sharma; Rupesh K Srivastava; Satyawati Sharma; Marco Tutone; Pradeep Kumar Singour
Journal:  Molecules       Date:  2022-08-31       Impact factor: 4.927

5.  In silico Design of Novel HIV-1 NNRTIs Based on Combined Modeling Studies of Dihydrofuro[3,4-d]pyrimidines.

Authors:  Yanming Chen; Yafeng Tian; Ya Gao; Fengshou Wu; Xiaogang Luo; Xiulian Ju; Genyan Liu
Journal:  Front Chem       Date:  2020-03-24       Impact factor: 5.221

6.  In Silico Design, Synthesis, and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity.

Authors:  Giulia Culletta; Mario Allegra; Anna Maria Almerico; Ignazio Restivo; Marco Tutone
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.